Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma [Phase 3]
Phase 3 trial to evaluate odronextamab versus rituximab with chemotherapy in adults with previously untreated follicular lymphoma; currently…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells [Phase 2]
Phase 2 study investigating fecal microbiota transplant to remodel gut microbiota in patients with relapsed/refractory diffuse large B-cell …
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma [Phase 2]
A Phase 2 trial of response-adapted therapy with copanlisib plus rituximab in previously untreated follicular lymphoma; results were posted …
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
A multi-center registry sponsored by Tempus AI aims to discover molecular biomarkers across hematologic malignancies, including acute myeloi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma [Phase 1, Phase 2]
This document outlines an ongoing Phase 1/2 dose-escalation and dose-expansion trial of MDX2003 in multiple lymphoma types, including Walden…
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma [Phase 1]
Phase 1 trial results show safety and preliminary efficacy for ALLO-501, an allogeneic anti-CD19 CAR-T therapy, in adults with relapsed/refr…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
A clinical trial evaluating the EZH2 inhibitor tazemetostat in adults with follicular lymphoma who have received at least two prior therapie…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial evaluating initial therapy with Umbralisib plus Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma was terminated,…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma [Phase 2]
This Phase 2 trial evaluates rituximab and pembrolizumab with or without lenalidomide in relapsed follicular lymphoma and diffuse large B-ce…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial evaluating CC-99282 in combination with Rituximab given early after CAR T therapy in patients with relapsed or refractory B-ce…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma [Phase 1, Phase 2]
This clinical trial update outlines a study evaluating the combination of radiation therapy and rituximab for early-stage follicular lymphom…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL [Phase 2]
A Phase 2 clinical trial examining Surovatamig (AZD0486) as monotherapy in relapsed/refractory B-cell non-Hodgkin lymphoma, including follic…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Long-term Follow up Local Registry Study of Kymriah in South Korea
This clinical trial update reports a long-term follow-up local registry study of Kymriah in South Korea. Recruitment is ongoing for patients…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignanci…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab [Phase 1, Phase 2]
BeiGene announced completion and posted results for a Phase 1/2 study of BGB-10188 as monotherapy and in combination with zanubrutinib and t…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]
Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epco, Zanu, Ritux for R/R FL or MZL [Phase 2]
Phase 2 clinical trial recruiting to evaluate Epco, Zanu, and rituximab in relapsed/refractory follicular lymphoma and marginal zone lymphom…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A pharmacokinetic study is evaluating how crushing venetoclax tablets and dissolving them in solution affects drug exposure, to assess alter…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of Zanubrutinib, Rituximab, Lenalidomide (ZR²) in combination with Tislelizumab fo…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R [NA]
A single-arm, non-randomized pilot trial to evaluate the safety of autologous anti-CD19 CAR-T cells (ARI-0001) and the feasibility of local …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
A real-world study is evaluating subcutaneous epcoritamab in adults with diffuse large B-cell lymphoma and follicular lymphoma and is curren…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas [Phase 3]
This clinical trial update describes a Phase 3 study evaluating reduced-dose radiation therapy for people with B-cell lymphomas, specificall…